MediWound Ltd..
MDWD.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
MediWound Ltd. is a biopharmaceutical company specializing in the development, manufacture, and commercialization of novel, cost-effective, bio-therapeutic solutions for tissue repair and regenerative medicine. Their primary focus is on severe burn and wound management. The company's key products in...Show More
Better Health for All
40
MediWound's core products demonstrate revolutionary health benefits. NexoBrid for pediatric burns shows faster eschar removal (median 1 day vs. 6 days for standard of care), reduced wound area excised (1.5% vs. 48.1%), and significantly reduced need for surgery (8.3% vs. 64.4%).
1
It achieved complete debridement in 94.9% of adults and 100% of children in an expanded access protocol.
2
EscharEx for venous leg ulcers achieved complete debridement in 63% of patients compared to 13.3% for standard of care, with a median debridement time of 9 days versus 59 days.
3
MW005 for basal cell carcinoma showed complete histological clearance in some patients.
4
The company's products do not have established negative health outcomes. All products (NexoBrid, EscharEx, MW005) have demonstrated safety profiles comparable to or better than standard of care or placebo, with EscharEx showing a lower deep wound infection rate (11% vs. 38% for a competitor).
5
NexoBrid's development was supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA) under contract HHSO100201500035C, which funded pivotal clinical studies, marketing approval, procurement, and expanded access protocols, indicating substantial investment in health innovation.
6
While the NexoBrid expanded access protocol treated 239 patients, including 24 children, no specific data on the percentage of vulnerable populations reached is provided.
7
Fair Money & Economic Opportunity
0
MediWound Ltd. is a biopharmaceutical company focused on developing and commercializing therapeutic products for severe burns and wounds.
1
The company's business model does not involve lending, insuring, moving, or storing money for consumers, nor does it offer any financial products or services.
2
Therefore, all Key Performance Indicators related to fair money and economic opportunity, which are designed for financial institutions, are not applicable to MediWound Ltd.'s operations.
Fair Pay & Worker Respect
0
No specific, concrete data points for MDWD.US regarding fair pay and worker respect were found in the provided articles. pertains to Mölnlycke, a different company, and indicates an inability to access the cited external website, thus providing no information.
1
Fair Trade & Ethical Sourcing
0
The provided articles do not contain any specific, concrete data points or information relevant to MediWound Ltd.'s fair trade and ethical sourcing practices. There is no evidence regarding fair-trade certifications, supplier audit frequency, forced or child labor incidents in the supply chain, traceability coverage, remediation speed for supply chain violations, ethical clauses in supplier contracts, materials risk index, or supplier diversity spend.
1
The only audit mentioned is a GMP manufacturing audit for the company's own operations, which is not relevant to supplier-related ethical sourcing KPIs.
2
Honest & Fair Business
-50
MediWound Ltd. has a formal whistleblower policy that allows for anonymous and confidential reporting of financial concerns, including accounting, internal controls, or auditing matters, via a secure web form, mail, or hotline.
1
A 14-16 digit code is provided for message status tracking.
2
However, there is no evidence regarding independent investigation processes for these reports. The company also has an anti-corruption policy in place, but no details are provided on its scope, enforcement, or specific guidance.
3
Kind to Animals
-60
MediWound's animal testing policy is characterized by its reliance on animal models for product development and regulatory approval. The company is conducting a study that involves the development of a porcine (pig) hard-to-heal wound model to assess the efficacy of a debridement agent.
1
The FDA has agreed that the development of NexoBrid® falls under the Animal Rule, indicating that animal testing is required for this product.
2
This suggests that legal mandates for testing override the use of alternatives. The study uses a large animal model (pigs) with the ability to create 10 wounds on a single animal, and the wound remains open for approximately 40 days.
3
The company's use of pigs for wound models, without any mention of humane certifications or ethical practices for these animals, indicates extreme confinement practices where animals have no ability to express natural behaviors.
No War, No Weapons
0
No evidence available to assess MediWound Ltd. on No War, No Weapons.
Planet-Friendly Business
0
The provided articles contain no specific, concrete data points regarding MediWound Ltd.'s (MDWD.US) environmental performance, emissions, renewable energy use, water management, waste diversion, or any other sustainability metrics relevant to the 'Planet-Friendly Business' value. Information found in some articles pertains to Mölnlycke Health Care, a strategic partner and investor, and not to MediWound Ltd. itself.
1
Respect for Cultures & Communities
0
The provided articles focus on MediWound Ltd.'s financial performance, product information, leadership, and distribution agreements. No specific, concrete data points or facts were found regarding the company's engagement with local or indigenous communities, cultural impact assessments, local employment ratios, grievance mechanisms, cultural preservation efforts, or any other metrics related to respect for cultures and communities.
Safe & Smart Tech
0
The company's privacy policy outlines user rights to access, rectify, erase, object to, and request data portability, which aligns with industry-standard user privacy controls.
1
The policy also mentions compliance with applicable laws, including GDPR, indicating basic regulatory compliance.
2
Additionally, the policy states data retention for legal and regulatory reasons, reflecting standard data collection and retention practices.
3
Zero Waste & Sustainable Products
0
No specific, concrete data points were found in the provided articles for MediWound Ltd. (MDWD.US) regarding any of the Key Performance Indicators related to Zero Waste & Sustainable Products.
1
The articles discuss general industry trends, challenges, and best practices in pharmaceutical waste management and packaging, but do not provide company-specific quantitative data, initiatives, or performance metrics for MDWD.US.
2